

**From:** SANTE CONSULT-C1  
**Sent:** jeudi 27 mai 2021 16:10  
**To:** [REDACTED] (SANTE)  
**Subject:** FW: EU Therapeutics Strategy clarification

---

**From:** [REDACTED] <[\[REDACTED\]@acumen-publicaffairs.com](mailto:[REDACTED]@acumen-publicaffairs.com)>  
**Sent:** Monday, May 17, 2021 5:02 PM  
**To:** [REDACTED] (SANTE) <[\[REDACTED\]@ec.europa.eu](mailto:[REDACTED]@ec.europa.eu)>  
**Subject:** EU Therapeutics Strategy clarification

Dear [REDACTED],

Thank you very much for your time on the phone just now and for agreeing to send over some additional information by email on the Therapeutics Strategy. It would be great if you were able to assist with any information on the following questions and any other points you feel would be relevant:

- What the process will be for arriving at 3 therapeutics by October 2021? The Strategy says that the Commission's aim is to have '*three new therapeutics available (my emphasis) by October 2021 and possibly two more by the end of the year.*' The Strategy stated that by June there will be a broader portfolio of ten potential COVID-19 therapeutics and the identification of five of the most promising ones. Would the additional two by the end of the year be from these five selected in June?
- What is the foreseen role of Member States in relation to the Therapeutics Strategy and whether this will be the same as for COVID vaccines?
- Will Advance Purchase Agreements happen at EU level and will participation by Member States be voluntary? Linked to this, would EU level negotiations on APAs rule out MS individually negotiating with the same commercial partners?

Any additional light they could shed on some of these topics would be very helpful.

Kind regards,

[REDACTED]

[REDACTED]

M: + 32 [REDACTED]

[Linkedin](#) | [Twitter](#)

**Acumen**  
public affairs

EU Transparency Register ID: 85679286747-21